The prognostic implications of SIRTs expression in breast cancer: a systematic review and meta-analysis

Abstract

Abstract Background Sirtuins (SIRTs) have key roles in cancer progression. However, the prognostic implications of SIRTs in breast cancer (BC) remains a subject of debate and controversy. Thus, we performed a meta-analysis to identify the precise prognostic value of SIRTs in BC patients. Methods Systematic literature searching was conducted in PubMed, Cochrane Library, Web of Science, and Embase databases. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate the association of SIRTs expression and survival outcomes in BC patients. Results A total of 22 original studies with 6317 patients were eligible for this meta-analysis. The results showed that in patients with BC, elevated SIRTs levels were associated with shorter overall survival (OS) and disease-free survival (DFS) both in univariate (HR = 1.56, 95% CI 1.21–2.00; HR = 1.67, 95% CI 1.32–2.12, respectively) and multivariate analysis models (HR = 2.11, 95% CI 1.48–3.00; HR = 1.70, 95% CI 1.20–2.39, respectively). Notably, further subgroup analysis revealed that overexpression of SIRT1 and SIRT6 predicted poor OS (HR = 2.65, 95% CI 1.54–4.56; HR = 2.53, 95% CI 1.64–3.90, respectively) and DFS (HR = 1.65, 95% CI 1.07–2.56; HR = 2.74; 95% CI 1.88–4.01, respectively) in BC. Conclusions Our data has elucidated that SIRT1 and SIRT6 could serve as prognostic biomarkers for patients with BC and may contribute to refined patient management.

Keywords

• SIRTs
• Breast cancer
• Prognosis
• Meta-analysis